

# Massive pulmonary embolism presenting as disseminated intravascular coagulation

William T Hart MD\*

Carl P Hallenborg MD\*\*

*Disseminated intravascular coagulation (DIC) can be defined as evidence of activation of the coagulation mechanism resulting in proteolysis of fibrinogen by thrombin and plasmin and an acute thrombocytopenia.*

*The association of pulmonary embolism (PE) with DIC has recently been reported but in reviewing recent textbooks of hematology, there is no mention of PE as a cause of DIC<sup>1,7</sup>.*

*Clinicians need to be made aware of this association since it affects the patient who is thought to be autoanticoagulated as well as the patient who has DIC of unknown cause. PE needs to be included in the differential diagnosis of an autoanticoagulated state and in DIC of unknown etiology. In both instances the recommended treatment is full-dose intravenous heparin therapy<sup>1,5,7</sup>.*

Pulmonary embolism accounts for an estimated 300,000 hospitalizations and as many as 50,000 deaths annually<sup>6</sup>. Despite advances in diagnostic imaging it may go undetected until postmortem examination. Recognition of the association between DIC and pulmonary embolism may enhance the accuracy of the clinical diagnosis.

We report 2 cases of an unusual presentation of a massive PE and DIC.

---

\* Chief Medical Resident  
Department of Medicine  
John A Burns School of Medicine

\*\* Chief, Pulmonary Division  
Department of Medicine  
John A Burns School of Medicine

Presented at the American College of Physicians, Hawaii Scientific Meeting, March 15, 1991.

Address correspondence to:  
William T Hart MD  
Division of Pulmonary and Critical Care Medicare  
Department of Medicine  
Stanford University Medical Center  
Stanford, CA 94305-5236

Received for publication May 17, 1991.

## Case reports

### Case 1

A 47-year-old Japanese man complained of a sudden onset of shortness of breath, hemoptysis and near loss of consciousness. Twelve days earlier he had undergone coronary artery bypass grafting.

He was known to have had diabetes mellitus and hypertension. Physical examination revealed left lung-field crackles. The admission chest roentgenogram demonstrated a small left pleural effusion. Laboratory tests were remarkable for thrombocytopenia. On arterial blood gas analysis, he had a widened A-a gradient.

A pulmonary angiogram demonstrated multiple bilateral pulmonary emboli. The patient subsequently developed bleeding into the thigh, thrombocytopenia, and other coagulation abnormalities. Fibrin split products (FSP) were increased, resulting in a decrease of the fibrinogen level. A bone-marrow aspiration was read as normal. A diagnosis of DIC was made. The patient recovered after treatment with full heparinization.

### Case 2

An 80-year-old Caucasian woman with a history of steroid-dependent chronic obstructive pulmonary disease was admitted to hospital for treatment of *Pseudomonas pneumonia*. CBC and platelets were normal at admission.

Her medical history was also notable for congestive heart failure. Physical examination revealed dyspnea without cyanosis. The patient had a prolonged hospital course due to persistent weakness and shortness of breath. Primary hyperthyroidism was then diagnosed. An acute anemia developed. FSP were increased and the fibrinogen level was decreased. Acute thrombocytopenia developed and DIC was diagnosed. Heparin was not instituted given the presence of hematologic abnormalities. The patient died and at autopsy a massive, saddle, pulmonary embolus was found completely occluding both right and left lungs.

## Discussion

Case 1 clinically illustrates DIC associated with a pulmonary embolus. Specifically, there was an acute thrombocytopenia and evidence of activation of the coagulation mechanism resulting in proteolysis of fibrinogen by thrombin and plasmin. This is the definition of DIC<sup>7</sup>.

(Continued on page 125) ►

The biochemical abnormalities can be detected by testing for circulating fibrin monomers and fibrin-degradation products. Once the occurrence of PE and DIC was recognized, treatment with heparin corrected the hematologic abnormalities and allowed the patient to recover.

Case 2 serves as a reminder that even in those clinical settings in which DIC can occur, PE may be present and should be considered even if laboratory examination suggests autoanticoagulation. The presence of an autoanticoagulation picture should not deter the clinician from treating with full doses of heparin, since the autoanticoagulation may represent DIC secondary to PE<sup>1,5,6</sup>.

This association between PE and DIC is not well known<sup>17</sup>. The proposed mechanisms by which PE may result in DIC include: Liberation of tissue factors, endothelial damage, vascular malformation, decreased blood flow<sup>7</sup>.

Stahl studied this association in 6 patients with DIC of unknown etiology and in each case he was able to document, by pulmonary angiogram or scanning, coexisting PE. Included were patients with DIC and DVT, DIC after aortic valve replacement, DIC after uncomplicated hemicolectomy for a benign villous adenoma, DIC and ulcerative colitis, DIC post-abdominal aortic surgery and DIC after a cesarean section. All cases were found to have coagulation abnormalities and evidence of DIC with thrombocytopenia. Full-dose heparin treatment resolved their hematologic abnormalities as well as their pulmonary emboli<sup>1</sup>.

PE associated with an elevation of FSP was first described by Merskey. Elevated FSP was thought to represent the defibrination syndrome wherein fibrinolysis was the result of degradation and resolution of emboli<sup>2</sup>. Recent evidence suggests that PE itself activates the coagulation mechanism resulting in increased FSP and decreased fibrinogen levels; this activation is not expected to occur from fibrinolysis of an embolus.

Support for this concept comes from the finding that the fibrin formed after embolization has occurred is different from the fibrin in the original embolus itself. A study in dogs in which an I-125 fibrin-labeled autologous clot was embolized into the dog lung, revealed that the subsequent appearance of fibrin degradation products did not contain the radioactive label. Heparin given just prior to embolization was able to markedly inhibit the consumption of fibrinogen and the production of degradation products<sup>8</sup>. This suggests further evidence that DIC occurred secondary to PE; rather than fibrinolysis of the embolus.

This appears to be a specific activation that occurs in the lung; patients with thrombophlebitis or deep venous thrombosis give no evidence of DIC or of an increase in FSP unless there is also a PE<sup>3,8</sup>. In a study of 46 patients with suspected PE, the concentration of FSP when compared with the angiographic findings revealed that FSP was increased above 10 micrograms per milliliter in 19 patients with angiographically documented PE and were not elevated at all in the 22 patients

(Continued on page 134) ►

## WHEN EXPERIENCE COUNTS, COUNT ON HAWAIIAN TAX-FREE TRUST.

Yes, Hawaiian Tax-Free Trust is an investment you can count on. As the first and largest fund in the Islands investing in municipal bonds, the Trust offers one of the few remaining ways to earn tax-free income together with a high level of safety.

Moreover, as a resident of Hawaii your income from the Trust is free of *both* Federal and State of Hawaii income taxes.\*

Best of all, you get experienced, locally-based investment management by

Hawaiian Trust Co., Ltd.— people you know and can count on.

You'll also enjoy:

- a high-grade, widely diversified portfolio
- monthly dividends\*\* by check, or reinvested for you *without* sales charge
- ready liquidity\*\*
- high current return
- low initial investment - \$1,000

**DOUBLE  
TAX-FREE  
INCOME**

Make an investment that you and Hawaii can count on. For details, talk to your broker. Or call the Trust toll-free today.

**1-800-228-4227**  
**HAWAIIAN  
TAX-FREE TRUST**



\* Under some circumstances, a small portion of income may be subject to tax for certain investors. \*\* Share value and dividend rates are not fixed and vary with interest rate fluctuations. Redemptions are at the current net asset value which may be more or less than cost.

© 1992 Aquila Distributors, Inc.

Aquila Distributors, Inc.  
820 Mililani Street, Suite 400, Honolulu, Hawaii 96813

**YES**, tell me more about how I can earn high monthly income and pay no Federal and State income taxes with the Hawaiian Tax-Free Trust. Please send a free prospectus containing more complete information, including all fees and expenses. I will read it carefully before I invest or send money.

Please print clearly

Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Home Phone: ( \_\_\_\_\_ ) \_\_\_\_\_

Business Phone: ( \_\_\_\_\_ ) \_\_\_\_\_ HMJ

# YOCON<sup>®</sup>

## YOHIMBINE HCl

**Description:** Yohimbine is a 3a-15a-20B-17a-hydroxy Yohimbine-16a-carboxylic acid methyl ester. The alkaloid is found in Rubaceae and related trees. Also in *Rauwolfia Serpentina* (L) Benth. Yohimbine is an indolalkylamine alkaloid with chemical similarity to reserpine. It is a crystalline powder, odorless. Each compressed tablet contains (1/12 gr.) 5.4 mg of Yohimbine Hydrochloride.

**Action:** Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its action on peripheral blood vessels resembles that of reserpine, though it is weaker and of short duration. Yohimbine's peripheral autonomic nervous system effect is to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both.

Yohimbine exerts a stimulating action on the mood and may increase anxiety. Such actions have not been adequately studied or related to dosage although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalamic centers and release of posterior pituitary hormone.

Reportedly, Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by B-adrenergic receptors, its effect on blood pressure, if any, would be to lower it; however no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage.

**Indications:** Yocon<sup>®</sup> is indicated as a sympatholytic and mydriatic. It may have activity as an aphrodisiac.

**Contraindications:** Renal diseases, and patient's sensitive to the drug. In view of the limited and inadequate information at hand, no precise tabulation can be offered of additional contraindications.

**Warning:** Generally, this drug is not proposed for use in females and certainly must not be used during pregnancy. Neither is this drug proposed for use in pediatric, geriatric or cardio-renal patients with gastric or duodenal ulcer history. Nor should it be used in conjunction with mood-modifying drugs such as antidepressants, or in psychiatric patients in general.

**Adverse Reactions:** Yohimbine readily penetrates the (CNS) and produces a complex pattern of responses in lower doses than required to produce peripheral a-adrenergic blockade. These include, anti-diuresis, a general picture of central excitation including elevation of blood pressure and heart rate, increased motor activity, irritability and tremor. Sweating, nausea and vomiting are common after parenteral administration of the drug.<sup>1,2</sup> Also dizziness, headache, skin flushing reported when used orally.<sup>1,3</sup>

**Dosage and Administration:** Experimental dosage reported in treatment of erectile impotence.<sup>1,3,4</sup> 1 tablet (5.4 mg) 3 times a day, to adult males taken orally. Occasional side effects reported with this dosage are nausea, dizziness or nervousness. In the event of side effects dosage to be reduced to 1/2 tablet 3 times a day, followed by gradual increases to 1 tablet 3 times a day. Reported therapy not more than 10 weeks.<sup>3</sup>

**How Supplied:** Oral tablets of Yocon<sup>®</sup> 1/12 gr. 5.4 mg in bottles of 100's NDC 53159-001-01 and 1000's NDC 53159-001-10.

**References:**

1. A. Morales et al., *New England Journal of Medicine*: 1221, November 12, 1981.
2. Goodman, Gilman — *The Pharmacological basis of Therapeutics* 6th ed., p. 176-188. McMillan December Rev. 1/85.
3. *Weekly Urological Clinical letter*, 27:2, July 4, 1983.
4. A. Morales et al., *The Journal of Urology* 128: 45-47, 1982.

Rev. 1/85



AVAILABLE AT PHARMACIES NATIONWIDE

**PALISADES PHARMACEUTICALS, INC.**

219 County Road  
Tenafly, New Jersey 07670  
(201) 569-8502  
1-800-237-9083

**MASSIVE PULMONARY** (Continued from page 125)

that were negative for PE. There were 5 patients with equivocal findings<sup>4</sup>.

**Conclusion**

Pulmonary embolism should be included in the differential diagnosis of DIC of unknown origin because prompt treatment with full-dose heparin will correct the hematologic abnormalities as well and may be lifesaving. An autoanticoagulated state does not always prevent the formation of thrombi, and it may obscure an occult PE. The presence of FSP may add to the understanding of the pathophysiology in PE and may be a laboratory clue that can assist in the management of both PE and DIC. This occurrence merits wider recognition by clinicians and further studies need to be conducted.

**REFERENCES**

1. Stahl RB, Javid JP, Lackner H. Unrecognized pulmonary embolism presenting as disseminated intravascular coagulation. *Am J Med* 1984; 76:772-78.
2. Merskey C, Kleiner GJ, Johnson AJ. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. *Blood* 1966; 28:1-18.
3. Wilson JE, Frenkel EP, Pierce AK, et al. Spontaneous fibrinolysis in pulmonary embolism. *J Clin Invest* 1971; 50:474-480.
4. Rickman FD, Handin R, Howe JP, Alpert JS, Dexter L, Dalen JE. Fibrin split products in acute pulmonary embolism. *Ann Intern Med* 1973; 79:664-668.
5. Pesola GR, Carlon GC. Pulmonary embolus-induced disseminated intravascular coagulation. *Crit Care Med* 1987; 15:983-84.
6. Wong CK, Lau CP, Cheng CH, Ng WF. Occult fatal pulmonary embolism with disseminated intravascular coagulation, an unusual case masquerading as miliary tuberculosis. *Chest* 1990; 98:1288-90.
7. Wintrobe MM, Lee GR, Boggs DR, et al. Acquired coagulation disorders. IN: Wintrobe MM, Lee GR, Boggs DR, eds. *Clinical hematology*. Philadelphia: Lea & Febiger, 1981;1206-1246.
8. Cade J, Hirsh J, Regoeczi E. Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism. *Blood* 1975; 45:563-568.



**A New HMA Membership Benefit for HMA Members Only!**

*An Opportunity You Can't Beat!*

Get fleet prices on all Lexus models  
Also available to members on the Neighbor Islands

Call Brian Walker at 545-3987  
or drop by their showroom at

**Lexus of Hawaii**

744 Ala Moana Boulevard

A Division of Servco Pacific Inc.